By David Bautz, PhD NASDAQ: ICU READ THE FULL ICU RESEARCH REPORT Business Update Presentations Highlight SAVE Registry Data ...
– Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab abstracts ...
PHILADELPHIA and VANCOUVER, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (BCTX) (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT ...
NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that key data from across its dermatology portfolio, including multiple late-breaking abstracts, will be presented at the ...
Presenting ten abstracts including observations on long-term safety, disease progression, and decline in muscle contractile area with givinostat Encore oral presentation also highlights analyses from ...